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Objectives: Ipilimumab improved the survival of advanced melanoma patients in 
phase III trials (MDX010-20 [previously treated patients] and CA184-024 [treatment 
naïve patients]). Uncertainty exists, however, whether this benefit can be translated 
to real-world clinical practice. We investigated the use and survival outcomes of 
ipilimumab in The Netherlands. MethOds: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Survival outcomes 
(overall survival [OS] and one-year survival) in patients receiving ipilimumab in 
clinical practice were assessed using Kaplan-Meier estimates, and were compared 
with outcomes of pivotal trials and outcomes of real-world patients diagnosed 
before the introduction of ipilimumab (2003-2011; stage IV only) using data from 
the Dutch Comprehensive Cancer Centres. Results: From 2012-2015, 545 patients 
received at least one dose of ipilimumab in real-world practice (65% received four 
dosages; median follow-up 4.6 months; data cut-off March 9, 2015). Ipilimumab 
was most frequently prescribed in the second line (60%), followed by the first (31%), 
third (8%), and fourth line (2%), respectively. Median OS was 7.7 months (IQR:3.6-NR) 
and one-year survival was 40%. This is somewhat lower than in the pivotal trials, 
which may be due to differences in baseline characteristics and time of follow-up 
(MDX010-20: median follow-up 27.8 months, median OS 10.1 months, one-year 
survival 46%; CA184-024: median follow-up 11.0 months, median OS 11.2 months, 
one-year survival 48%). However, the survival was higher compared to the survival 
in the period before the introduction of ipilimumab (2003-2011: median OS 6.8 
months [IQR:3.3-18.5], one-year survival 33%). cOnclusiOns: Melanoma survival 
has improved since the introduction of ipilimumab. Although survival was some-
what lower in real-world compared to pivotal trials, a survival benefit was observed 
in Dutch real-world clinical practice.
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Objectives: Traditionally, patients who survive 5 years from diagnosis of cancer 
are considered to be cured. More recent analysis of adjusted mortality rates sug-
gests this assumption may not be valid. We sought to identify data on relative 
survival at 10 to 20 years for common cancers to determine which showed a 
continuing increase in mortality beyond 5 years. MethOds: National or regional 
cancer databases reporting net or relative survival beyond 5 years from diagno-
sis were identified, with 5- and 10-year data available from England and Wales, 
Scotland, the USA, Switzerland and Slovakia; 5-, 10- and 15-year data from Norway; 
and 5-, 10-, 15- and 20-year data from Germany and Sweden. The percentage 
decrease in net survival at each 5-year step was calculated at 10, 15 and 20 years 
to identify where there was a persistent increase in all-cause mortality above 
expected for the age- and sex-adjusted cancer-free population. Results: Regional 
setting had a large impact on relative survival for each type of cancer. However, 
oropharyngeal, head and neck, liver, lung, pancreatic and ovarian cancers, chronic 
lymphocytic leukaemia, mesothelioma, multiple myeloma, and Kaposi’s sarcoma 
consistently showed between a 10% and 70% further decrease in relative survival 
at 10 compared with 5 years. A further 10% or greater decrease in relative sur-
vival was seen between 10 and 20 years from diagnosis for head and neck, lung, 
laryngeal and prostate cancer, and was around 40% lower than population norms 
at 20 years for people with multiple myeloma. cOnclusiOns: When modelling 
the impact of treatments for cancer, it is important to consider the whole period 
of increased risk of mortality. For certain cancers, in particular multiple myeloma, 
lung, prostate and laryngeal cancer, this may require a time horizon of 20 years 
or longer.
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Objectives: New drugs for advanced melanoma showed promising results in piv-
otal trials; however, uncertainty exists regarding their value in real-world clinical 
practice. We investigated real-world treatment patterns and outcomes of advanced 
melanoma in The Netherlands. MethOds: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Real-world treat-
ment patterns and outcomes (overall survival [OS], one-year survival and time-to-
next-treatment [TTNT]) were assessed in patients receiving systemic treatment 
Weights (IPCW), and Iterative Parameter Estimation (IPE). To determine acceptance 
of these techniques in Australia, Public Summary Documents (PSDs) reporting on the 
Pharmaceutical Benefits Advisory Committee’s (PBAC’s) decision-making in oncol-
ogy were reviewed. MethOds: Oncology PSDs were examined, and the method of 
adjustment (if any), PBAC concerns and outcome were assessed. Results: Thirty-
one submissions included trials allowing crossover; 16 (52%) presented adjusted 
estimates of OS. Common indications were: renal cell carcinoma, non-small cell 
lung cancer (NSCLC), melanoma, colorectal cancer (CRC), and pancreatic neuroendo-
crine tumour. The most common method was RPSFT (11 products), followed by IPCW 
(4 products). IPE, marginal structural modelling, and a two-stage Weibull approach 
were each reported once. The RPSFT approach appeared to raise fewer concerns 
than the IPCW, usually because the IPCW correction was considered less reliable 
when a high proportion of patients crossed-over. In NSCLC and CRC, the PBAC con-
sidered unadjusted crossover to be appropriate and reflect a relevant comparison 
between first- and second-line therapy. Only five PSDs reported results of more 
than one method. The PBAC expressed a preference to see a range of approaches 
and a clearly justified selection of the most appropriate method. cOnclusiOns: A 
range of adjustment techniques were used to support submissions in Australia, with 
RPSFT being most common. It is important to clearly justify the need for adjustment 
and the selection of the most appropriate technique.
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Objectives: In oncology an important parameter of safety is the potential treat-
ment error in hospitals. The hypothesis which is being analyzed in the underlying 
work is the potential benefit of hospitals from a safety reduction through fix-
dose ready to use subcutaneous therapies in comparison to intravenous therapies 
with trastuzumab and rituximab. MethOds: For the calculation of risk levels the 
Failure Mode and Effect Analysis (FMEA) approach was being applied. Within that 
approach the critical treatment path is followed and risk classification for each 
individual step is being estimated. For the oncology and hematology administra-
tion there were 35 different risk steps assessed. The study was executed in 17 
hematology and 16 breast cancer centers in Italy. Results: When the risk classes 
are calculated there were eight high risk areas identified for the administration 
of an intravenous therapy in hematology or oncology, 13 areas would be defined 
as having a median risk and 14 areas as having a low risk classification (total risk 
areas: n= 35). When the new subcutaneous formulation would be applied 23 dif-
ferent risk levels could be completely eliminated (65% reduction). Including those 
eliminations important high risk classes such as the following were included: 
dose calculation, preparation and package labeling, preparation of the access to 
the vene and pump infusion preparation and infusion monitoring. The overall risk 
level for the intravenous administration was estimated to be 756 (ex-ante) and 
could be significantly reduced by 70% (ex-post). The potential harm compensation 
for errors related to the pharmacy would be decreased from 234’271 € for eight 
risk classes to only 3 risk classes. cOnclusiOns: The use of a subcutaneous 
administration of trastuzumab (breast cancer) and rituximab (hematology) might 
lower the risk of administration and treatment errors for patients and could hence 
indirectly have a positive financial impact for hospitals.
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Objectives: There is a paucity of study to examine the relationship between 
metformin use and hepatocellular carcinoma (HCC) specific survival or recur-
rence. We, therefore, conducted a nationwide population-based study in the 
patients with HCC who underwent curative resection to investigate whether 
metformin use would reduce mortality and recurrence rate. MethOds: The 
study population initially included 105,367 adults who had a primary diagno-
sis of HCC (International Classification of Diseases, 10th revision, C22) from the 
Korea Center Cancer Registry between 1 January 2005 and 31 December 2011. 
The primary outcome was HCC-specific survival. We obtained HCC deaths from 
the National Population Registry of the Korea National Statistical Office through 
December 31, 2013, with the use of a unique personal identification number. The 
secondary outcome was tumor recurrence during follow-up periods from National 
Health Insurance Service. Results: The HCC-related survival or recurrence-free 
was significantly higher in the metformin user group than in the metformin non-
user group during the follow-up period. In unadjusted analyses, compared to 
non-metformin group, metformin group showed a significant lower risk of HCC-
specific death (hazard ratio (HR), 0.40; 95% Confidence interval (CI), 0.32-0.51). 
After multivariable adjustments for clinical covariates, metformin group still had 
a significantly lower risk of events as compared with non-metformin group (HR, 
0.38; 95% CI, 0.30-0.49). The adjusted risk for recurrence was also significantly 
lower in metformin group (HR, 0.41; 95% CI, 0.33-0.52) compared with that of non-
metformin group. cOnclusiOns: Among patients of HCC cohort treated with 
curative hepatic resection, metformin use was associated with improvement of 
HCC-specific mortality and recurrence risk.
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mutation. The sensitivity and specificity of Cobas 4800 BRAF V600 in vitro diag-
nostic test is excessively high to detect the V600 mutation. In the BRIM-3 study, 
vemurafenib showed improved PFS and OS in patients carrying BRAF mutation. 
Our aim is to analyze the vemurafenib international and local real-life survival data 
of the patients treated in the National Institute of Oncology, in case of individual 
reimbursement application. MethOds: We retrospectively assessed the single 
centre Hungarian real-life survival data from 2012 to May 2015. We compared the 
outcome of the Hungarian and the French real-life and BRIM-3 data. Results: In 
the selection of the patient group suitable for BRAFi therapy, we carried out 277 
BRAF mutation analysis with Cobas test during the given period. 148 cases were 
wide type, the mutation rate was 46,57% with 129 mutant cases. In Hungary, BRAFi 
therapy is reimbursed, only on the basis of individual reimbursement application. 36 
MM patients were enrolled, with median age of 53,5 years. The median PFS reached 
5,4 months, the OS reached 12,3 months. In the previously published French single 
centre trial, in temporary authorisation program, the median PFS was 3,6 months, 
the median OS was 7,5 months. The BRIM-3 study demonstrated mPFS 6,9 months 
and OS 13,6 months. cOnclusiOns: The detection of BRAF mutation is essential 
in the therapeutic strategy of metastatic melanoma patients. The Cobas 4800 BRAF 
test allows a more exact selection of the patient group to be treated by BRAFi. 
Our single centre OS data are close to BRIM3 clinical trial data. In case of previous 
vemurafenib therapy started in appropriate treatment line, further improvement 
can be expected in survival results.
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Objectives: To estimate the budget impact in Belgium of denosumab (120 mg) 
in the treatment of GCTB, an extremely rare, locally aggressive benign tumor 
often leading to severe destruction of bone and extension into the surround-
ing soft tissues. MethOds: A budget impact model was developed, combining 
epidemiological data, proportions of resectable and unresectable GCTB disease, 
and eligibility for treatment with denosumab. Evidence collected in clinical tri-
als is used to estimate the denosumab clinical effect. Publicly available costs of 
the relevant surgical procedures and the actual cost for denosumab 120 mg from 
payer perspective are considered. The clinical effect of denosumab in delaying 
or downgrading invasive surgeries is estimated by comparing the surgical pro-
cedures planned at trial entry and the procedures actually performed during the 
trial. To calculate the savings in surgical procedures, the downgrade in planned 
procedures and only 50% of the avoided procedures in the trial period were con-
sidered. Resource use associated with the surgical procedures included the need 
for rehabilitation and re-hospitalizations due to complications. Savings were only 
applied to patients with resectable tumors. The model does not take into account 
the full clinical benefit of denosumab including decrease in disease progression 
in patients who have not undergone surgery. The time horizon considered was 3 
years. Results: Denosumab is expected to be provided to 32, 42 and 53 patients in 
year 1, 2 and 3, respectively. 550,940 euros of total drug expenditure are expected. 
Savings were estimated at 409,372 euros, the majority of which was attributable 
to fewer and less severesurgical procedures. The impact of denosumab on the 
overall health care budget is 141,568 euros over three years. cOnclusiOns: The 
introduction of denosumab in the treatment of GCTB has a manageable budget 
impact in Belgium. Seventy four percent of the denosumab expenditure is off-set 
thanks to its clinical benefit.
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Objectives: CML is among seven nosologies included in the federal program 
for supply of medicines to patients with rare diseases in the Russian Federation. 
Currently only first-generation tyrosine kinase inhibitor - imatinib is available to 
CML patients within this program. However from 25% to 30% of CML patients in 
Russia have intolerance or develop resistance to imatinib and require second line 
therapy with dasatinib or nilotinib. MethOds: This study includes budget impact 
analysis (BIA) for dasatinib as a second-line CML therapy. Only direct pharmaco-
therapy costs were considered. Annual treatment cost of dasatinib amounts to 
1,720,111 rubles (28,365 € ) for chronic phase. Time horizon was set at 1 year. In 
the baseline scenario it was assumed that 100% of the imatinib-resistant patients 
are treated with high-dose imatinib in frame of the federal “seven nosologies” 
program. In the future scenario upon dasatinib inclusion into aforementioned 
program the percentage of patients that would be possible to switch from high-
dose imatinib to dasatinib without increase of the total national CML budget was 
calculated. Also annual economic impact of providing dasatinib as a second-line 
therapy to 100% of the eligible patients was estimated. Assumptions regarding 
adherence to treatment of patients diagnosed with CML and actual medica-
tion consumption rate were included into analysis. Results: Budget impact 
analysis was carried out for a total population of 7100 patients according to the 
national CML registry in 2015. Centralized purchase of dasatinib in frame of the 
federal program could save 463 mln rubles (7,7 mln € ) or 10% of the actual total 
CML budget in Russia. cOnclusiOns: With consideration for actual dasatinib 
use within regional drug provision programs it was demonstrated that 100% of 
the imatinib-resistant and intolerant patients can be provided with dasatinib 
using Kaplan-Meier estimates. Additional data from the Dutch Comprehensive 
Cancer Centres (stage IV only) were used to compare survival outcomes in two 
time periods (2003-2011 versus 2012-2015). Results: From 2012-2015, 1259 patients 
received systemic treatment (median follow-up 12.6 months; data cut-off March 
09, 2015). The most frequently prescribed treatments were ipilimumab (29%) and 
vemurafenib (29%), followed by trial-based treatments (27%), chemotherapy (11%), 
and dabrafenib (4%). Vemurafenib was the most frequently applied treatment in the 
first line (41%), ipilimumab in the second line (56%), and trial-based treatments in 
the third and fourth line (41% and 63%, respectively). The median TTNT was 5.4, 4.7 
and 4.3 months in the first, second, and third line, respectively. The median OS was 
9.6 months (IQR 4.6-18.6) and the one-year survival was 41% (unresectable stage IIIc 
[n= 33]: median OS 32.8 months, one-year survival 71%; stage IV [n= 1226]: median 
OS 9.3 months, one-year survival 40%). In contrast, survival outcomes of stage IV 
melanoma were much lower in the period before the introduction of new drugs 
(2003-2011: median OS 6.8 months, one-year OS 33%). cOnclusiOns: Melanoma 
survival has improved since the introduction of new drugs for advanced melanoma. 
The survival gain shown in pivotal trials was also observed in real-world clinical 
practice in The Netherlands.
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Objectives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age 
in 3-D format to identify cohort and other effects in specific cancers. MethOds: 
The Requiem model analysed and smoothed ONS mortality statistics for England 
and Wales from 1970 to 2013 by single year of age and gender. Disease codes were 
mapped at 4-digit level from ICD-8 to ICD-10 by medical modellers. An analysis 
was run for total cancer mortality and individual malignant diseases within that 
category. Outputs were displayed in multiple formats, including 3-D images of cen-
tral mortality and deaths by age over time, and heat maps of absolute mortality 
improvement per disease and the component each disease contributed to all-cause 
mortality trends. Results: Cancer mortality increased from 1970 to 1990s and has 
since fallen by up to 4% per year, accounting for a 1-2% of absolute improvement 
in all-cause mortality, and with evidence from heat maps for cohort effects. Most 
cancers showed increasing mortality rates to the 1990s, which have now declined. 
This is seen particularly in men in lung cancer, which saw up to 10% improvement 
per year in mortality, in breast cancer in women, with a peak in the 1980s and up 
to 20% annual improvement since then, and in colon cancer in both genders, with 
a 5-10% annual improvement in mortality per year. Hodgkin’s lymphoma mor-
tality has decreased steadily in both genders, while non-Hodgkin’s mortality has 
increased in the over 50s. Mortality continues to worsen for liver, kidney and CNS 
cancers. Pancreatic cancer has shown little change in mortality since 1970 in either 
gender. cOnclusiOns: The Requiem model 3-D visualisation facilitates the under-
standing of trends in mortality for different cancers, and shows the impact of cohort 
effects and risk factors such as smoking and alcohol.
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Objectives: Ipilimumab is licensed for the treatment of adults with advanced (unre-
sectable or metastatic) malignant melanoma. It was approved for reimbursement in 
Ireland in 2012, through the Oncology Drug Management System (ODMS). The ODMS 
was introduced by the National Cancer Control programme in July 2012. The scheme 
allows direct hospital reimbursement for approved high cost anti-cancer drugs 
for individual patients. Drugs must be prescribed for approved indications accord-
ing to license informed protocols. The online based system is designed to collect 
information from hospitals (26 nationally) in relation to patient demographic data, 
cancer drug use and spending. This data is maintained by the payer (Primary Care 
Reimbursement Service (PCRS)). The objective of this study is to examine this real 
world data of patients treated with ipilimumab. MethOds: The PCRS extracted data 
on all patients who had received ≥ 1 dose of ipilimumab ( June 2012 - May 2015) in the 
public hospital setting through the ODMS. Patient data included patient demograph-
ics, the quantity of ipilimumab supplied and the reimbursement claim data. The 
National Centre for Pharmacoeconomics analysed this anonymised data. Kaplan-
Meier survival curves were constructed using the Tierney et al methodology. Survival 
data was extrapolated using the Hoyle and Henley methodology. Results: A total 
of 205 patients who had received ≥ 1 dose ipilimumab over the period of analysis 
were identified. The mean age of the cohort was 60.4 years (SD ±14) and 58.5% were 
male. All 4 cycles of ipilimumab were received by 59% of patients. Seven patients 
were re-treated with the drug. Empirical and extrapolated real world survival data 
were compared to clinical trial evidence. cOnclusiOns: The analysis provides 
real world survival outcomes for patients with advanced malignant melanoma 
treated with ipilimumab in Ireland. Examination of this evidence is prudent in 
advance of the launch of the PD1 inhibitors for malignant melanoma.
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Objectives: The selection of the MM patient group, eligible for BRAFi therapy is 
based on the molecular pathologic diagnostics of the BRAF V600 gain-of-function 
